BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16015041)

  • 21. Mapping of genetic deletions on chromosome 3 in colorectal cancer: loss of 3p25-pter is associated with distant metastasis and poor survival.
    Tsai MH; Fang WH; Lin SH; Tzeng ST; Huang CS; Yen SJ; Chou SJ; Yang YC
    Ann Surg Oncol; 2011 Sep; 18(9):2662-70. PubMed ID: 21347784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7.
    Boulay JL; Mild G; Reuter J; Lagrange M; Terracciano L; Lowy A; Laffer U; Orth B; Metzger U; Stamm B; Martinoli S; Herrmann R; Rochlitz C
    Genes Chromosomes Cancer; 2001 Jul; 31(3):240-7. PubMed ID: 11391794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SMAD4 as a prognostic marker in colorectal cancer.
    Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
    Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
    Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer--a study matched for tumor depth and pathology.
    Tanaka T; Watanabe T; Kazama Y; Tanaka J; Kanazawa T; Kazama S; Nagawa H
    J Surg Oncol; 2008 Jan; 97(1):69-73. PubMed ID: 17786972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
    Kawakami K; Matsunoki A; Kaneko M; Saito K; Watanabe G; Minamoto T
    Cancer Sci; 2011 Jan; 102(1):166-74. PubMed ID: 21087350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.
    Mild G; Bachmann F; Boulay JL; Glatz K; Laffer U; Lowy A; Metzger U; Reuter J; Terracciano L; Herrmann R; Rochlitz C
    Int J Cancer; 2002 Nov; 102(3):254-7. PubMed ID: 12397645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
    Ochiai T; Nishimura K; Noguchi H; Kitajima M; Tsuruoka Y; Takahashi Y; Tsukada A; Watanabe E; Nagaoka I; Futagawa S
    J Surg Oncol; 2006 Jul; 94(1):45-50. PubMed ID: 16788943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of 18q LOH in sporadic colorectal carcinoma.
    Pilozzi E; Ferri M; Onelli MR; Mercantini P; Corigliano N; Duranti E; Dionisi L; Felicioni F; Virgilio E; Ziparo V; Ruco L
    Am Surg; 2011 Jan; 77(1):38-43. PubMed ID: 21396303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Cho YY; Moon JH; Park JY; Jeon SW; Lee IT; Choi GS; Jun SH
    Clin Cancer Res; 2008 Jan; 14(1):62-6. PubMed ID: 18172253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelic status of chromosomes 17p, 18q, 22q [corrected] 3p and their clinical usefulness in colorectal cancer.
    Fujita S; Baba H; Yamamoto S; Akasu T; Moriya Y; Sugano K
    Anticancer Res; 2006; 26(4B):2833-40. PubMed ID: 16886602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
    Park CM; Lee WY; Chun HK; Cho YB; Yun HR; Heo JS; Yun SH; Kim HC
    J Surg Oncol; 2010 Jan; 101(1):22-7. PubMed ID: 19798689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
    Boulay JL; Mild G; Lowy A; Reuter J; Lagrange M; Terracciano L; Laffer U; Herrmann R; Rochlitz C
    Br J Cancer; 2002 Sep; 87(6):630-4. PubMed ID: 12237773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SMAD7 is a prognostic marker in patients with colorectal cancer.
    Boulay JL; Mild G; Lowy A; Reuter J; Lagrange M; Terracciano L; Laffer U; Herrmann R; Rochlitz C
    Int J Cancer; 2003 Apr; 104(4):446-9. PubMed ID: 12584741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.